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Abstract
Background: Angiotensin II type 1 receptor (AT1R) blockers lower the incidence of ischemic stroke in hypertensive
patients and attenuate brain inflammation and injury in animal models. Although AT1R on both blood cells (BC)
and vascular endothelial cells (EC) can be activated by angiotensin II (Ang II) to elicit inflammation, little is known
about the relative contributions of AT1R expressed on BC and EC to the brain injury responses to ischemia and
reperfusion (I/R) in the setting of angiotensin-induced hypertension.
Methods: The contributions of BC- and EC-associated AT1R to I/R-induced brain inflammation and injury were
evaluated using wild type (WT), AT1aR
-/-, and bone marrow chimera mice with either a BC+/EC+ (WT®WT) or BC-/
EC+ (AT1aR
-/-®WT) distribution of AT1aR. The adhesion of leukocytes and platelets in venules, blood brain barrier
(BBB) permeability and infarct volume were monitored in postischemic brain of normotensive and Ang II-induced
hypertensive mice.
Results: The inflammatory (blood cell adhesion) and injury (BBB permeability, infarct volume) responses were
greatly exaggerated in the presence of Ang II-induced hypertension. The Ang II-enhanced responses were
significantly blunted in AT1aR
-/- mice. A similar level of protection was noted in AT1aR
-/- ®WT mice for BBB
permeability and infarct volume, while less or no protection was evident for leukocyte and platelet adhesion,
respectively.
Conclusions: BC- and EC-associated AT1aR are both involved in the brain injury responses to ischemic stroke
during Ang II-hypertension, with EC AT1aR contributing more to the blood cell recruitment response and BC
AT1aR exerting a significant influence on the BBB disruption and tissue necrosis elicited by I/R.
Keywords: angiotensin II type 1 receptor, blood brain barrier, bone marrow chimera, cerebral ischemia,
inflammation
Background
The renin-angiotensin system (RAS) has been implicated
in the pathogenesis of different cardiovascular (CV) dis-
eases, including stroke. Angiotensin II (Ang II), the prin-
cipal effector molecule of the RAS, exerts some
deleterious effects on the vasculature of different organ
systems via its pressor properties and the resultant
elevation of blood pressure. An additional component of
t h ev a s c u l a rd y s f u n c t i o na n dt i s s u ei n j u r yr e s p o n s e
mediated by Ang II has been attributed to the ability of
the peptide to induce a pro-inflammatory, pro-thrombo-
genic, and pro-oxidative phenotype in both large and
microscopic blood vessels [1-3]. Both the vasomotor and
inflammatory effects of Ang II involve the activation of
angiotensin II type 1 receptors (AT1R) that are
expressed on leukocytes and platelets, endothelial cells
and vascular smooth muscle. Engagement of Ang II to
AT1R results in the activation of these cells, and the
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and/or release of different inflammatory proteins, such
as cytokines and adhesion glycoproteins. While endothe-
lial cell-associated AT1R has received much attention as
an integral component of the pathophysiology of differ-
ent CV diseases, recent studies have revealed that AT1R
expressed on bone marrow (BM)-derived cells can also
make a significant contribution to disease pathogenesis.
For example, it has been reported that apolipoprotein E-
deficient (ApoE
-/-)B Mc h i m e r i cm i c ew i t hA T 1 R
-/-
blood cells and AT1R
+/+ vessel wall components exhibit
blunted Ang II-enhanced atherosclerosis, comparable to
that noted in AT1R
-/-/ApoE
-/- double knockout mice,
suggesting that AT1R on BM derived cells is critical for
the progression of atherosclerosis [4]. Similarly, blood
cell-associated AT1R has been implicated in the vaso-
motor dysfunction that accompanies Ang II-induced
hypertension [5] and the enhanced inflammatory cell
adhesion observed in venules of hypercholesterolemic
mice [6] while recent report showed the protective effect
of BM-derived cells on Ang II-induced hypertension [7].
Angiotensin II has been implicated in the pathogenesis
of ischemic and hemorrhagic stroke. Animal studies
have revealed that AT1R blockers blunt the brain
inflammation and tissue injury response to ischemia and
reperfusion (I/R) [8]. Reduced ischemic lesion areas
after brain I/R have also been detected in mice that are
genetically deficient in either AT1R [9,10] or angiotensi-
nogen [11], while an exaggerated brain injury response
(mediated through AT1R) has been noted in renin/
angiotensinogen transgenic mice [12,13]. Acute [14] or
chronic [15,16] administration of Ang II in WT mice
has been shown to induce the adhesion of leukocytes
and platelets, and compromise blood brain barrier (BBB)
function in the cerebral microvasculature. These
responses to exogenous Ang II were dependent on
AT1R activation and the production of reactive oxygen
species, but independent of the elevated blood pressure.
In the presence of exogenously administered Ang II, I/R
elicit more intense brain inflammatory and tissue injury
responses that are prevented by pharmacological AT1R
blockade [14]. While the existing literature strongly
implicates AT1R in the brain injury resulting from
ischemic stroke in both normotensive and Ang II-hyper-
tensive animals, the cell populations that contribute to
the AT1R-dependent cerebral microvascular dysfunction
and brain injury response to I/R remain undefined.
Gene cloning studies of AT1R have revealed that mice
and rats have two subtypes of AT1R (AT1aR and
AT1bR) whereas human have only one receptor type
[17]. The functions of the two receptors found in
rodents are largely indistinguishable, with AT1aR mak-
ing a more substantial contribution to blood pressure
regulation [18]. Consequently, AT1aR knockout mice
have been widely employed to assess the physiologic
and pathophysiologic roles of the angiotensin II type 1
receptors [3,6].
Hence, the overall objective of this study was to deter-
mine the relative contributions of AT1R expressed on
blood cells vs endothelial cells to the brain injury
responses elicited by I/R in both normotensive and Ang
II-hypertensive mice. This objective was achieved by
comparing the injury and inflammatory responses of the
cerebral microvasculature to I/R in WT and AT1aR
-/-
mice to the responses elicited in AT1aR
-/- BM chimeras
that were absent AT1aR on BM-derived cells while
expressing AT1aR on the vascular wall. Our findings are
consistent with injury response-specific contributions of
both blood cell- and vascular wall associated AT1aR to
ischemic stroke in both normotensive and Ang II-hyper-
tensive mice.
Methods
Animals
Male C57Bl/6J WT mice (n = 120), AT1aR
-/- mice
(B6.129P2-Agtr
1tm1Unc/J) (Jackson Laboratories Bar Har-
bor) (n = 35), and BM chimeric mice (n = 81) were stu-
died. All experimental procedures involving the use of
animals were reviewed and approved by the Institutional
Animal Care and Use Committee of LSU Health
Sciences Center and performed according to the Guide
for the Care and Use of Laboratory Animals outlined by
the National Institutes of Health.
BM Chimeras
WT to WT (WT®WT, n = 41) and AT1aR
-/- to WT
(AT1aR
-/-®WT, n = 40) BM chimeras were produced,
as previously described [15], by transplanting BM from
either WT or AT1aR
-/- into WT mice. In brief, BM
cells, collected from the femurs and tibias of donor mice
were injected (2 × 10
6 BM cells) via the femoral vein
into recipient mice (congenic WT with same phenotype
as C57BL/6J mice; B6.SJLPtprc
aPep3
b/BoyJ), following
total-body irradiation sufficient to eliminate the recipi-
ent’s blood cells. The BM chimeras were housed in
autoclaved cages, with 0.2% neomycin added to drinking
water for the first two weeks. After six to eight weeks,
reconstitution of BM cells was verified using flow cyto-
metry by testing for the % blood leukocytes positive for
CD45.1 (recipient isoform of CD45) vs CD45.2 (donor
isoform of CD45). We used BM chimeras in which >
90% of recipient marrow was replaced by donor BM.
Angiotensin II infusion
Mice received a 14-day infusion of either saline or Ang
II (Bachem Americas, Inc.) using micro-osmotic pumps
(Durect Corporation), which were implanted subcuta-
neously in the intrascapular region under isofluorane
Nagai et al. Experimental & Translational Stroke Medicine 2011, 3:15
http://www.etsmjournal.com/content/3/1/15
Page 2 of 9anesthesia. Sterile procedures were used and a topical
antibiotic Neosporin (Johnson & Johnson) was applied
to prevent postoperative infection at the site of implan-
tation. The pumps in the control group were loaded
with only the saline vehicle, while the experimental
groups received Ang II loaded pumps that delivered the
peptide at a rate of 2000 ng/kg/min. In some experi-
ments, a range of Ang II doses (400 - 2000 ng/kg/min)
were used to determine the dose-dependent responses
of leukocyte and platelet adhesion, and blood pressure
to Ang II in the absence of I/R.
Blood pressure
Measurements of blood pressure in conscious mice were
obtained using a tapered femoral artery catheter
implanted (under isofluorane anesthesia) three hours
prior to data collection via a pressure transducer
coupled to a computer system, as previously described
[15]. Mean arterial pressure was recorded over the 1-
hour period preceding the experiment.
Middle cerebral artery occlusion and reperfusion
Transient (45 minutes) focal cerebral ischemia was
induced in ketamine (100 mg/kg, i.p., Lloyd Labora-
tories) and xylazine (10 mg/kg, i.p., Hospira, Inc.)
anesthetized mice by occluding the right middle cerebral
artery with 7-0 silicone-coated nylon monofilament
(Doccol Corp.). After the 45-minute occlusion period,
the nylon fiber was gently removed and the common
carotid artery was reopened [19,20]. In sham mice, the
arteries were visualized but not disturbed. Ischemia and
reperfusion were verified using a laser Doppler flow-
meter (ML191 Blood Flow Meter, ADInstruments) to
monitor cerebral blood flow. We have demonstrated
that middle cerebral artery occlusion is associated with
a 90% reduction in brain perfusion [21]. Core tempera-
ture was kept at 36 - 37°C.
Intravital videomicroscopy
Four hours following reperfusion after middle cerebral
artery occlusion, mice were anesthetized with ketamine
(100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) then
prepared for intravital microscopic observation and
evaluation of the cerebral microvasculature, as pre-
viously described [22,23]. Briefly, cerebral venules (100
μml e n g t h ,2 5 - 5 0μm diameter) were viewed through a
cranial window using an upright fluorescent micro-
scope using a 20× water immersion lens. Color images
were captured with a 3 charge coupled device color
video camera. Ex vivo carboxyfluorescein diacetate suc-
cinimidyl ester (CFDSE) (Molecular Probes, Invitrogen)
labeled platelets (100 × 10
6 cells) derived from a
matching donor mouse were administered for visuali-
zation and quantification of (green) adherent platelets.
Rhodamine 6G (Sigma Chemical) was administered for
detection of leukocytes (red). Adherent leukocytes and
platelets were defined as cells bound to the venular
wall for ≥ 30 and 2 seconds, respectively [6,15]. Cell
adhesion data are expressed as number of cells per
millimeter squared of venular surface, calculated from
venular diameter and length, assuming cylindrical
geometry.
Infarct Volume
After 24 hours of reperfusion, mice were decapitated
under deep anesthesia with ketamine (200 mg/kg, i.p.)
and xylazine (20 mg/kg, i.p.) then 1-mm-thick coronal
sections of the brain were immersed in 0.05% 2,3,5-tri-
phenyltetrazolium chloride (TTC, Sigma-Aldrich) solu-
tion for 30 minutes. The total areas of each brain
section and the infarct region were quantified with the
software program, NIH image. Infarct volume was cor-
rected for edema as previously described [23].
BBB Dysfunction
Changes in the barrier properties of the cerebral micro-
vasculature were monitored using the Evans blue (EB)
extravasation method, as previously described [19,20]. A
2% solution of EB (Sigma-Aldrich) was administered (4
ml/kg, i.v.) immediately following I/R or after sham
operation. Twenty-four hours later, mice were anesthe-
tized with ketamine (100 mg/kg, i.p.) and xylazine (10
mg/kg, i.p.) then plasma sample was collected and brain
tissue (right hemisphere with brain stem and dura
mater removed) sample was collected after transcardial
perfusion with PBS (100 mm Hg, 5 minutes). EB con-
centrations were determined using a fluorescence spec-
trophotometer (FLUOstar Optima; BMG LABTECH,
Inc.). BBB permeability was estimated by dividing tissue
EB concentration (ng/g brain weight) by the plasma
concentration (ng/ml).
Statistical Analysis
All of the values are reported as mean ± SE. One-way
analysis of variance with Fisher’s post-hoc test was used
to determine statistical differences between groups. Sta-
tistical significance was set at P < 0.05.
Results
Blood pressure responses to chronic Ang II infusion
A two-week infusion of Ang II produced a dose-depen-
dent increase mean arterial pressure in WT mice (Figure
1A), with statistically significant increases noted at Ang
II infusion rates between 800 and 2000 ng/kg/min, com-
pared to saline infusion (controls). The increased blood
pressure induced by 2000 ng/kg/min Ang II in WT
mice, was not observed in either AT1aR
-/- or AT1aR
-/-
®WT mice (Table 1).
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cell adhesion in cerebral venules
In WT mice not subjected to cerebral I/R, chronic Ang
II infusion resulted in a large and significant increase in
the number of adherent leukocytes, the magnitude of
which did not differ between Ang II infusion rates of
400 and 2000 ng/kg/min (Figure 1B).
Roles of blood cell vs vascular wall AT1aR in cerebral I/R-
induced leukocyte adhesion in normotensive and Ang II-
hypertensive mice
In WT mice with a saline-loaded Alzet pump (Figure
2A), focal cerebral I/R elicited a significant increase in
leukocyte adhesion, which was not observed in AT1aR
-/-
mice. The leukocyte adhesion response in AT1aR
-/-
®WT mice did not differ from the WT®WT response.
The findings are consistent with a role for vessel wall-,
but not blood cell-, associated AT1aR in mediating the
leukocyte recruitment elicited by cerebral I/R.
In WT mice with an implanted Ang II-loaded pump
(Figure 2B), the numbers of adherent leukocytes
detected in cerebral venules were much higher than
observed in their saline pump counterparts, both in the
absence or presence of I/R. The significant increase in
leukocyte adhesion elicited by I/R during chronic Ang II
infusion was not observed in AT1aR
-/- mice. Unlike the
saline pump mice, AT1aR
-/-®WT mice exhibited a sig-
nificant but partial reduction in leukocyte adhesion
compared to their WT®WT counterparts. These find-
ings indicate that both vessel wall- and blood cell-asso-
ciated AT1aR contribute to the leukocyte recruitment
response to I/R during chronic Ang II infusion.
Platelet adhesion responses to chronic Ang II infusion:
Influence of I/R and AT1aR
In WT mice not subjected to cerebral I/R, chronic Ang
II infusion resulted in a dose-dependent increase in the
number of adherent platelets (Figure 1C). In a manner
similar to leukocyte adhesion, I/R elicited significant
increases in platelet adhesion in WT mice receiving
either a saline or Ang II infusion (Figure 3A &3B).
Unlike the leukocyte adhesion responses to I/R, a signif-
icant attenuation in platelet adhesion was noted after I/
Ro n l yi nA T 1 a R
-/- mice, with no differences noted
between WT®WT and AT1aR
-/-®WT mice during
either saline or Ang II infusion. These findings suggest
that vessel wall-, but not blood cell-, associated AT1aR
contributes to the I/R-induced platelet recruitment
response in the presence or absence of chronically ele-
vated Ang II levels.
Alterations in BBB function induced by I/R during chronic
Ang II infusion
Figure 4A summarizes the changes in BBB permeability
following I/R in mice implanted with a saline pump.
T h ed a t as h o w sat e n d e n c yf o ri n c r e a s e dB B Bp e r m e -
ability following I/R, which was more pronounced (and
statistically different) in the WT > WT chimeras com-
pared to WT controls. In mice receiving a chronic infu-
sion of Ang II (Figure 4B), a large and significant
increase in BBB permeability was noted after I/R. The I/
R-induced EB leakage was entirely prevented in both
AT1aR
-/- and AT1aR
-/-®WT mice, suggesting that
blood cell-associated AT1aR accounts for the impaired
endothelial function elicited by I/R in the presence of
chronically elevated Ang II levels. The trend for WT >
WT chimeras to exhibit a more robust response to I/R
than WT mice was more evident (and statistically
Figure 1 Chronic Ang II infusion elicits dose-dependent
increases in blood pressure and the adhesion of leukocytes
and platelets in cerebral venules. WT mice received a 14-day
infusion of Ang II subcutaneously in pumps loaded to deliver either
0, 400, 600, 800, 1000, or 2000 ng/Kg/min. (Panel A): Mean arterial
blood pressure was measured in conscious mice with an indwelling
femoral arterial catheter. (Panels B & C): The adhesion of leukocytes
(B) and platelets (C) in cerebral venules was monitored via a cranial
window by fluorescence intravital videomicroscopy. Leukocytes
were labeled in vivo with Rhodamin 6G while platelets were labeled
with CFDSE ex vivo. Data are shown as mean ± SEM for 6-13 mice
per Ang II dose. * denotes p < 0.05 relative to saline infusion.
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saline and AngII infusion responses therefore suggest
that the bone marrow transplantation procedure may
predispose the cerebral microvasculature to a more
exaggerated response to an inflammatory stimulus, like
I/R. This possibility is consistent with the findings of
published report [24].
Contributions of Ang II and AT1aR to tissue infarction
elicited by cerebral I/R
Focal cerebral I/R produced significant brain infarcts in
both saline- and Ang II-infused mice, with the Ang II
group exhibiting a 77% larger infarct (p < 0.05) than the
saline group (Figure 5A &5B). Highly significant and
nearly identical reductions in infarct volume were noted
Table 1 Chronic angiotensin II infusion (2000 ng/kg/min) induces hypertension via blood cell associated AT1aR.
Experimental group Mean arterial pressure
(mmHg)
Wild type mice (WT) - saline loaded (- saline)
(n = 9)
110.8 ± 1.8
WT - angiotensin II loaded (- Ang II)
(n = 10)
125.4 ± 4.9*
AT1aR knockout mice (AT1aR
-/-) - Ang II
(n = 6)
103.4 ± 4.0
†
WT bone marrow chimera mice reconstructed with WT bone marrow (WT®WT) - saline
(n = 7)
96.6 ± 2.0
WT®WT - Ang II
(n = 8)
115.1 ± 6.1
‡
AT1aR
-/-®WT - Ang II
(n = 6)
108.9 ± 3.2
†
Data are presented as mean ± SE. * denotes P < 0.05 vs WT - saline, † denotes p < 0.05 relative to WT - Ang II, ‡ denotes P < 0.05 vs WT®WT - saline
Figure 2 Cerebral I/R induces an AT1aR-dependent leukocyte recruitment response that is mediated by vascular wall-associated
AT1aR in normotensive mice, while blood cell-associated AT1aR mediates the response in Ang II hypertensive mice. Focal brain
ischemia (45 min) and reperfusion (4 hrs) were induced by occluding the middle cerebral artery using the intraluminal filament method.
Leukocyte-endothelial cell adhesion in cerebral venule was monitored through a cranial window by fluorescence intravital videomicroscopy.
Angiotensin (2000 ng/kg/min)(Panel B) or an equal volume of saline (Panel A) was infused over a 2 wk period in WT, AT1aR
-/-,W T ®WT BM
chimeric, and AT1aR
-/-®WT BM chimeric mice. Leukocytes were labeled in vivo with Rhodamin 6G for fluorescence. Data are shown as mean ±
SE with 5-7 mice per group. * denotes p < 0.05 relative to corresponding non-ischemic WT mice. † denotes p < 0.05 relative to corresponding
WT mice + I/R. ‡ denotes p < 0.05 relative to corresponding WT®WT BM chimeras.
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both normotensive and Ang II-induced hypertensive mice. Focal brain ischemia (45 min) and reperfusion (4 hrs) were induced by occluding
the middle cerebral artery using the intraluminal filament method. Platelet adhesion in cerebral venule was monitored through a cranial window
by fluorescence intravital videomicroscopy. Angiotensin (2000 ng/kg/min)(Panel B) or an equal volume of saline (Panel A) was infused over a 2
wk period in WT, AT1aR
-/-,W T ®WT BM chimeric, and AT1aR
-/-®WT BM chimeric mice. Platelets were labeled ex vivo with CFDSE. Data are
shown as mean ± SE with 5-7 mice per group. * denotes p < 0.05 relative to corresponding non-ischemic WT mice. † denotes p < 0.05 relative
to corresponding WT mice + I/R. n = 5-7 mice per group.
Figure 4 Cerebral I/R in Ang II hypertensive mice induces BBB disruption that is largely dependent on blood cell-associated AT1aR.
Focal brain ischemia (45 min) and reperfusion (24 hrs) were induced by occluding the middle cerebral artery using the intraluminal filament
method. Evan’s blue (EB) dye was administered at the time of reperfusion or sham operation. Twenty-four hours later, brain tissue and plasma
samples were collected for EB measurement. BBB permeability was estimated by dividing tissue EB concentration by plasma concentration in
saline (Panel A) or Ang II (2000 ng/kg/min, 2 wks)(Panel B) infused mice. The data are shown as mean ± SE with 5-7 mice per experimental
group. * denotes p < 0.05 relative to non-ischemic WT mice. † denotes p < 0.05 relative to WT mice + I/R. ‡ denotes p < 0.05 relative to
WT®WT BM chimeras. N.E.: no examination.
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-/- and AT1aR
-/-®WT mice subjected to I/R
in both saline- and Ang II-infused mice. These findings
suggest that blood cell-associated AT1aR are largely
responsible for the Ang II mediated tissue injury
observed following cerebral I/R in the absence or pre-
sence of chronically elevated Ang II levels.
Discussion
There are several published reports that implicate the
RAS in the pathogenesis of ischemic stroke. Clinical and
basic studies have revealed the ability of AT1R blockers
to reduce the incidence and protect tissue injury from
stroke independent of the blood pressure-lowering effect
[25-29], while animal studies demonstrate attenuated
inflammatory and injury responses in post-ischemic
brain following pharmacologic blockade or genetic dele-
tion of AT1R [8]. These findings have often been inter-
preted to reflect the pro-inflammatory response that
results from the activation of AT1R on vascular
endothelial cells [14,30]. However, recent studies of Ang
II-induced hypertension [5,7] and Ang II-accelerated
atherogenesis [4] have revealed a role for blood cell-
associated AT1R in mediating the inflammation and
vascular dysfunction/injury in these models of human
disease. The results of the present study provide new
insights regarding the relative contributions of blood
cell- and vessel wall-associated AT1aR to the brain
injury responses elicited by focal cerebral I/R in both
normotensive and Ang II-hypertensive mice.
Our finding that chronically elevated Ang II levels
results in an exaggerated brain injury response to I/R and
that genetic deficiency of AT1aR
-/- protects both normo-
tensive and Ang II-hypertensive mice against the cerebral
microvascular inflammation and tissue damage elicited
by I/R are consistent with the existing literature
[9,11-13]. However, our comparison of results from
AT1aR
-/- mice to AT1aR
-/-®WT BM chimeras reveal
distinct roles of vessel wall- and blood cell-associated
AT1aR as mediators of the blood cell recruitment and
brain injury responses to I/R. In both normotensive and
Figure 5 The brain infarction induced by cerebral I/R in both normotensive and Ang II hypertensive mice is largely dependent on
blood cell associated-AT1aR. Twenty four hours following focal cerebral ischemia (45 min), brain tissue slices were stained with TTC and
cerebral infarct volume was determined (using imaging software) from the regions not stained with the vital dye. This procedure was applied to
brain sections obtained from Ang II (2000 ng/kg/min, 2 wks) or saline infused WT, AT1aR
-/-,W T ®WT BM chimeric and AT1aR
-/-®WT BM chimeric
mice. Data are shown as mean ± SE with 5-6 mice per group. * denotes p < 0.05 relative to corresponding WT mice + I/R. † denotes p < 0.05
relative to corresponding WT®WT BM chimeras.
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appears to be largely responsible for promoting the
recruitment of leukocytes and platelets in cerebral micro-
vessels. This observation is consistent with reports that
describe endothelial cell responses to AT1R activation
that tend to induce a pro-adhesive surface on endothelial
cells, including a reduced expression of endothelial nitric
oxide synthase [31], an increased production/release of
reactive oxygen species [1,32] and cytokines [33], and an
increased expression of endothelial cell adhesion mole-
cules [34,35]. The dominant role of vessel wall AT1aR in
mediating the I/R-induced leukocyte- and platelet-
endothelial cell interactions may also reflect an influence
of locally high levels of Ang II generated by brain par-
enchyma, which would exert less influence on AT1aR on
BM-derived cells [27]. This could also explain why we
detected a contribution of blood cell-associated AT1aR
in I/R-induced recruitment of leukocytes (but not plate-
lets) in mice receiving exogenous Ang II.
In contrast to the inflammatory cell recruitment eli-
cited by cerebral I/R, the brain injury response, mani-
fested as an increased BBB permeability and increased
infarct size, appears to be mediated exclusively by
AT1aR expressed on blood cells. This dependency of
the I/R-induced injury response on blood cell-associated
AT1aR was evident especially in Ang II-hypertensive
mice. Recent in vitro [36] and in vivo [15] experiments
suggest that exposure of the cerebral microvasculature
(or monolayers of cultured cerebral microvascular
endothelial cells) to Ang II (in the absence of I/R)
results in an impairment of BBB function that is
mediated by endothelial AT1R. The absence of a role
for endothelial cell AT1aR in mediating the increased
BBB permeability following I/R in Ang II-hypertensive
mice suggests that either endothelial AT1aR are down-
regulated or become unresponsive to Ang II, and/or
that the direct effects of endothelial AT1aR activation
are overwhelmed by the actions of chemical mediators
released as a result of AT1aR activation on blood cells
including resident macrophages as well as circulating
cells [37]. The beneficial effects of blood cell AT1aR
deficiency could also reflect the actions of Ang II on
angiotensin II type-2 receptors, which have been shown
to exert significant neuroprotective effects against stroke
when stimulated on BM stromal cells [38].
While several previous studies have implicated the
recruitment of leukocytes and platelets in the brain
injury response to focal I/R [39,40], the results of the
present study indicate that the blood cell recruitment
and injury responses do not parallel one another when
BM-derived cells are devoid of AT1aR (in BM chi-
meras). The exact mechanisms by which AT1aR
expressed on BM derived cells mediate the tissue
damage elicited by focal ischemic stroke remain unclear.
H o w e v e r ,t h e s ef i n d i n g si n d i c a t et h a tf u t u r ew o r ki s
needed to identify the specific blood cell population that
mediates the deleterious effects of AT1aR activation in
ischemic stroke and suggest that strategies that target
blood cell-associated AT1aR may prove beneficial in
prevention or treatment of ischemic stroke and other
CV diseases.
Conclusion
Our comparison of the injury and inflammatory
responses of the cerebral microvasculature to I/R in
wild type, AT1aR
-/-,a n dA T 1 a R
-/-®WT chimeras has
revealed injury response-specific contributions of both
blood cell- and vascular wall associated AT1aR. The
results also indicate that AT1aRs expressed on BM-
derived cells play a major role in mediating the brain
inflammation and injury following ischemic stroke in
both normotensive and AngII-hypertensive mice. Addi-
tional work is needed to define the mechanism(s) that
underlie the brain injury response to AT1R activation
on BM-derived cells.
List of abbreviations used
Ang II: angiotensin II; AT1R: angiotensin II type 1 receptor; ApoE
-/-:
apolipoprotein E-deficient; AT1aR
-/-®WT: AT1aR
-/- to WT; BBB: blood brain
barrier; BC: blood cells; BM: bone marrow; CFDSE: carboxyfluorescein
diacetate succinimidyl ester; CV: cardiovascular; EC: endothelial cells; EB:
Evans blue; I/R: ischemia and reperfusion; RAS: renin-angiotensin system;
TTC: 2,3,5-triphenyltetrazolium chloride; WT: wild type; WT®WT: WT to WT.
Acknowledgements
The study was supported by funds from the Malcolm Feist Cardiovascular
Endowment and a grant from the National Heart Lung and Blood Institute
(HL26441)
Authors’ contributions
MN performed animal experiments, collected and analyzed the data, and
drafted the manuscript. ST also performed animal experiments, collected
and analyzed data, and contributed to the manuscript. SAV produced bone
marrow chimera mice, monitored blood pressure in conscious mice, and
collected cell adhesion data. SR collected and analyzed data from the TTC
and EB assays. GY collected and analyzed data from the EB assay. DNG
conceived of the study, participated in its design and coordination, and
helped draft the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 October 2011 Accepted: 16 November 2011
Published: 16 November 2011
References
1. Nickenig G, Harrison DG: The AT(1)-type angiotensin receptor in oxidative
stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation
2002, 105:530-536.
2. Alvarez A, Sanz MJ: Reactive oxygen species mediate angiotensin II-
induced leukocyte-endothelial cell interactions in vivo. J Leukoc Biol 2001,
70:199-206.
3. Petnehazy T, Cooper D, Stokes KY, Russell J, Wood KC, Granger DN:
Angiotensin II type 1 receptors and the intestinal microvascular
dysfunction induced by ischemia and reperfusion. Am J Physiol
Gastrointest Liver Physiol 2006, 290:G1203-1210.
Nagai et al. Experimental & Translational Stroke Medicine 2011, 3:15
http://www.etsmjournal.com/content/3/1/15
Page 8 of 94. Fukuda D, Sata M, Ishizaka N, Nagai R: Critical role of bone marrow
angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in
apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2008,
28:90-96.
5. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J,
Weyand C, Harrison DG: Role of the T cell in the genesis of angiotensin II
induced hypertension and vascular dysfunction. J Exp Med 2007,
204:2449-2460.
6. Petnehazy T, Stokes KY, Wood KC, Russell J, Granger DN: Role of blood
cell-associated AT1 receptors in the microvascular responses to
hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006, 26:313-318.
7. Crowley SD, Song Y-S, Sprung G, Griffiths R, Sparks M, Yan M, Burchette JL,
Howell DN, Lin EE, Okeiyi B, Stegbauer J, Yang Y, Tharaux P-L, Ruiz P: A role
for angiotensin II type 1 receptors on bone marrow-derived cells in the
pathogenesis of angiotensin II-dependent hypertension. Hypertension
2010, 55:99-108.
8. Hosomi N, Nishiyama A, Ban CR, Naya T, Takahashi T, Kohno M, Koziol JA:
Angiotensin type 1 receptor blockage improves ischemic injury
following transient focal cerebral ischemia. Neuroscience 2005,
134:225-231.
9. Walther T, Olah L, Harms C, Maul B, Bader M, Hörtnagl H, Schultheiss H-P,
Mies G: Ischemic injury in experimental stroke depends on angiotensin
II. FASEB J 2002, 16:169-176.
10. Iwai M, Liu H-W, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T,
Horiuchi M: Possible inhibition of focal cerebral ischemia by angiotensin
II type 2 receptor stimulation. Circulation 2004, 110:843-848.
11. Maeda K, Hata R, Bader M, Walther T, Hossmann KA: Larger anastomoses
in angiotensinogen-knockout mice attenuate early metabolic
disturbances after middle cerebral artery occlusion. J Cereb Blood Flow
Metab 1999, 19:1092-1098.
12. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H,
Mogi M, Higaki J, Horiuchi M: Exaggeration of focal cerebral ischemia in
transgenic mice carrying human Renin and human angiotensinogen
genes. Stroke 2009, 40:597-603.
13. Chen S, Li G, Zhang W, Wang J, Sigmund CD, Olson JE, Chen Y: Ischemia-
induced brain damage is enhanced in human renin and
angiotensinogen double-transgenic mice. Am J Physiol Regul Integr Comp
Physiol 2009, 297:R1526-1531.
14. Ishikawa M, Sekizuka E, Yamaguchi N, Nakadate H, Terao S, Granger DN,
Minamitani H: Angiotensin II type 1 receptor signaling contributes to
platelet-leukocyte-endothelial cell interactions in the cerebral
microvasculature. Am J Physiol Heart Circ Physiol 2007, 292:H2306-2315.
15. Vital SA, Terao S, Nagai M, Granger DN: Mechanisms Underlying the
Cerebral Microvascular Responses to Angiotensin II-Induced
Hypertension. Microcirculation 2010, 17:641-649.
16. Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T: Angiotensin II
induced cerebral microvascular inflammation and increased blood-brain
barrier permeability via oxidative stress. Neuroscience 2010, 171:852-858.
17. Sandberg K, Ji H, Clark AJ, Shapira H, Catt KJ: Cloning and expression of a
novel angiotensin II receptor subtype. Journal of Biological Chemistry 1992,
267:9455-9458.
18. Dasgupta C, Zhang L: Angiotensin II receptors and drug discovery in
cardiovascular disease. Drug Discovery Today 2011, 16:22-34.
19. Terao S, Yilmaz G, Stokes KY, Russell J, Ishikawa M, Kawase T, Granger DN:
Blood cell-derived RANTES mediates cerebral microvascular dysfunction,
inflammation, and tissue injury after focal ischemia-reperfusion. Stroke
2008, 39:2560-70.
20. Terao S, Yilmaz G, Stokes KY, Ishikawa M, Kawase T, Granger DN:
Inflammatory and injury responses to ischemic stroke in obese mice.
Stroke 2008, 39:943-950.
21. Yilmaz G, Arumugam TV, Stokes KY, Granger DN: Role of T lymphocytes
and interferon-gamma in ischemic stroke. Circulation 2006, 113:2105-2112.
22. Ishikawa M, Vowinkel T, Stokes KY, Arumugam TV, Yilmaz G, Nanda A,
Granger DN: CD40/CD40 ligand signaling in mouse cerebral
microvasculature after focal ischemia/reperfusion. Circulation 2005,
111:1690-1696.
23. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR: A
semiautomated method for measuring brain infarct volume. J Cereb
Blood Flow Metab 1990, 10:290-293.
24. Yuan H, Gaber MW, Boyd K, Wilson CM, Kiani MF, Merchant TE: Effects of
fractionated radiation on the brain vasculature in a murine model:
blood-brain barrier permeability, astrocyte proliferation, and
ultrastructural changes. Int J Radiat Oncol Biol Phys 2006, 66:860-866.
25. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U,
Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH,
Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and
mortality in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet
2002, 359:995-1003.
26. Ito T, Yamakawa H, Bregonzio C, Terrón JA, Falcón-Neri A, Saavedra JM:
Protection against ischemia and improvement of cerebral blood flow in
genetically hypertensive rats by chronic pretreatment with an
angiotensin II AT1 antagonist. Stroke 2002, 33:2297-2303.
27. Saavedra JM: Brain angiotensin II: new developments, unanswered
questions and therapeutic opportunities. Cell Mol Neurobiol 2005,
25:485-512.
28. Saad MAA, Abbas AM, Boshra V, Elkhateeb M, El Aal IA: Effect of
angiotensin II type 1 receptor blocker, candesartan, and beta 1
adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Acta Physiol Hung 2010, 97:159-171.
29. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J,
Zidek W, Dominiak P, Diener HC: Morbidity and Mortality After Stroke,
Eprosartan Compared with Nitrendipine for Secondary Prevention:
principal results of a prospective randomized controlled study (MOSES).
Stroke 2005, 36:1218-1226.
30. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM: Angiotensin II AT1
receptor blockade reverses pathological hypertrophy and inflammation
in brain microvessels of spontaneously hypertensive rats. Stroke 2004,
35:1726-1731.
31. Yamakawa H, Jezova M, Ando H, Saavedra JM: Normalization of
endothelial and inducible nitric oxide synthase expression in brain
microvessels of spontaneously hypertensive rats by angiotensin II AT1
receptor inhibition. J Cereb Blood Flow Metab 2003, 23:371-380.
32. Faraci FM, Lamping KG, Modrick ML, Ryan MJ, Sigmund CD, Didion SP:
Cerebral vascular effects of angiotensin II: new insights from genetic
models. J Cereb Blood Flow Metab 2006, 26:449-455.
33. Mateo T, Abu Nabah YN, Abu Taha M, Mata M, Cerdá-Nicolás M,
Proudfoot AEI, Stahl RAK, Issekutz AC, Cortijo J, Morcillo EJ, Jose PJ, Sanz M-
J: Angiotensin II-induced mononuclear leukocyte interactions with
arteriolar and venular endothelium are mediated by the release of
different CC chemokines. J Immunol 2006, 176:5577-5586.
34. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB:
Angiotensin II stimulates endothelial vascular cell adhesion molecule-1
via nuclear factor-kappaB activation induced by intracellular oxidative
stress. Arterioscler Thromb Vasc Biol 2000, 20:645-651.
35. Piqueras L, Kubes P, Alvarez A, O’Connor E, Issekutz AC, Esplugues JV,
Sanz MJ: Angiotensin II induces leukocyte-endothelial cell interactions in
vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation.
Circulation 2000, 102:2118-2123.
36. Fleegal-DeMotta MA, Doghu S, Banks WA: Angiotensin II modulates BBB
permeability via activation of the AT(1) receptor in brain endothelial
cells. J Cereb Blood Flow Metab 2009, 29:640-647.
37. Chinnery HR, Ruitenberg MJ, McMenamin PG: Novel characterization of
monocyte-derived cell populations in the meninges and choroid plexus
and their rates of replenishment in bone marrow chimeric mice. J
Neuropathol Exp Neurol 2010, 69:896-909.
38. Iwanami J, Mogi M, Li J-M, Tsukuda K, Min L-J, Sakata A, Fujita T, Iwai M,
Horiuchi M: Deletion of angiotensin II type 2 receptor attenuates
protective effects of bone marrow stromal cell treatment on ischemia-
reperfusion brain injury in mice. Stroke 2008, 39:2554-2559.
39. Yilmaz G, Granger DN: Leukocyte Recruitment and Ischemic Brain Injury.
Neuromol Med 2009, 12:193-204.
40. Stoll G, Kleinschnitz C, Nieswandt B: Combating innate inflammation: a
new paradigm for acute treatment of stroke? Ann NY Acad Sci 2010,
1207:149-154.
doi:10.1186/2040-7378-3-15
Cite this article as: Nagai et al.: Role of blood cell-associated
angiotensin II type 1 receptors in the cerebral microvascular response
to ischemic stroke during angiotensin-induced hypertension.
Experimental & Translational Stroke Medicine 2011 3:15.
Nagai et al. Experimental & Translational Stroke Medicine 2011, 3:15
http://www.etsmjournal.com/content/3/1/15
Page 9 of 9